Access the full text.
Sign up today, get DeepDyve free for 14 days.
(Paz-Ares L, Luft A, Vicente D, ; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051. doi:10.1056/NEJMoa181086530280635)
Paz-Ares L, Luft A, Vicente D, ; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051. doi:10.1056/NEJMoa181086530280635Paz-Ares L, Luft A, Vicente D, ; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051. doi:10.1056/NEJMoa181086530280635, Paz-Ares L, Luft A, Vicente D, ; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051. doi:10.1056/NEJMoa181086530280635
L. Paz-Ares, A. Spira, D. Raben, D. Planchard, B. Cho, M. Ozguroglu, D. Daniel, A. Villegas, D. Vicente, R. Hui, S. Murakami, D. Spigel, S. Senan, Corey Langer, Pérez Ba, A. Boothman, H. Broadhurst, C. Wadsworth, P. Dennis, S. Antonia, C. Faivre-Finn (2020)
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.Annals of oncology : official journal of the European Society for Medical Oncology
(Agulnik J, Kasymjanova G, Pepe C, . Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec. Curr Oncol. 2020;27(5):e459-e466. doi:10.3747/co.27.624133173385)
Agulnik J, Kasymjanova G, Pepe C, . Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec. Curr Oncol. 2020;27(5):e459-e466. doi:10.3747/co.27.624133173385Agulnik J, Kasymjanova G, Pepe C, . Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec. Curr Oncol. 2020;27(5):e459-e466. doi:10.3747/co.27.624133173385, Agulnik J, Kasymjanova G, Pepe C, . Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec. Curr Oncol. 2020;27(5):e459-e466. doi:10.3747/co.27.624133173385
Borghaei (2020)
4867Cancer, 126
(Choy H, Schwartzberg LS, Dakhil SR, . Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol. 2013;8(10):1308-1316. doi:10.1097/JTO.0b013e3182a0254623981966)
Choy H, Schwartzberg LS, Dakhil SR, . Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol. 2013;8(10):1308-1316. doi:10.1097/JTO.0b013e3182a0254623981966Choy H, Schwartzberg LS, Dakhil SR, . Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol. 2013;8(10):1308-1316. doi:10.1097/JTO.0b013e3182a0254623981966, Choy H, Schwartzberg LS, Dakhil SR, . Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol. 2013;8(10):1308-1316. doi:10.1097/JTO.0b013e3182a0254623981966
(Borghaei H, Langer CJ, Paz-Ares L, . Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. Cancer. 2020;126(22):4867-4877. doi:10.1002/cncr.3314232914866)
Borghaei H, Langer CJ, Paz-Ares L, . Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. Cancer. 2020;126(22):4867-4877. doi:10.1002/cncr.3314232914866Borghaei H, Langer CJ, Paz-Ares L, . Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. Cancer. 2020;126(22):4867-4877. doi:10.1002/cncr.3314232914866, Borghaei H, Langer CJ, Paz-Ares L, . Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. Cancer. 2020;126(22):4867-4877. doi:10.1002/cncr.3314232914866
(2020)
without tumor PD - L 1 expression : a pooled analysis of 3 randomized controlled trials
Steven Lin, Y. Lin, L. Yao, N. Kalhor, B. Carter, M. Altan, G. Blumenschein, L. Byers, F. Fossella, D. Gibbons, J. Kurie, Charles Lu, G. Simon, F. Skoulidis, Joe Chang, M. Jeter, Z. Liao, D. Gomez, M. O’Reilly, V. Papadimitrakopoulou, P. Thall, J. Heymach, A. Tsao (2019)
Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(Antonia SJ, Villegas A, Daniel D, ; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. doi:10.1056/NEJMoa170993728885881)
Antonia SJ, Villegas A, Daniel D, ; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. doi:10.1056/NEJMoa170993728885881Antonia SJ, Villegas A, Daniel D, ; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. doi:10.1056/NEJMoa170993728885881, Antonia SJ, Villegas A, Daniel D, ; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. doi:10.1056/NEJMoa170993728885881
T. Mok, Yi‐Long Wu, I. Kudaba, D. Kowalski, B. Cho, H. Turna, G. Castro, V. Srimuninnimit, K. Laktionov, I. Bondarenko, K. Kubota, G. Lubiniecki, Jin Zhang, D. Kush, G. Lopes, G. Adamchuk, M. Ahn, A. Alexandru, O. Altundag, A. Alyasova, O. Andrusenko, K. Aoe, A. Araújo, O. Aren, O. Rodriguez, T. Ativitavas, Oscar Avendano, F. Barata, C. Barrios, C. Beato, Per Bergstrom, D. Betticher, L. Bolotina, Michiel Botha, Sayeuri Buddu, C. Caglevic, A. Cardona, H. Castro, F. Senler, Carlos Cerny, A. Česas, G. Chan, Jian-hua Chang, Gongyan Chen, Xi Chen, S. Cheng, Ying Cheng, N. Cherciu, C. Chiu, S. Cicėnas, D. Ciurescu, G. Cohen, Marcos Costa, P. Danchaivijitr, F. Angelis, S. Azevedo, M. Dediu, Ts Deliverski, P. Marchi, Flor Valles, Z. Ding, Boyan Doganov, L. Dreosti, R. Duarte, Regina Edusma-Dy, S. Emelyanov, M. Erman, Yun Fan, L. Fein, Jifeng Feng, D. Fenton, G. Fernandes, C. Ferreira, F. Franke, H. Freitas, Y. Fujisaka, H. Galindo, Christina Galvez, D. Ganea, N. Gil, G. Girotto, E. Goker, T. Goksel, Gonzalo Aubin, Luis Wolff, H. Griph, M. Gumus, Jacqueline Hall, Greg Hart, L. Havel, Jianxing He, Yong He, C. Hernández, V. Hespanhol, T. Hirashima, Chung-man. Ho, A. Horiike, Y. Hosomi, K. Hotta, M. Hou, S. How, T. Hsia, Yi Hu, M. Ichiki, F. Imamura, O. Ivashchuk, Y. Iwamoto, J. Jaal, J. Jassem, Christa Jordaan, R. Juergens, D. Kaen, E. Kalinka‐Warzocha, N. Karaseva, B. Karaszewska, A. Każarnowicz, K. Kasahara, N. Katakami, T. Kato, T. Kawaguchi, J. Kim, K. Kishi, V. Kolek, Marchela Koleva, P. Kolman, L. Koubková, R. Kowalyszyn, D. Kowalski, K. Koynov, D. Ksienski, T. Kurata, G. Kuusk, L. Kuzina, I. Laczó, G. Ladrera, K. Laktionov, G. Landers, S. Lazarev, G. Lerzo, Krzysztof Kmak, Wei Li, C. Liam, Igor Lifirenko, O. Lipatov, Xiaoqing Liu, Zhe Liu, S. Lo, Valeria Lopes, Karla Lopez, Shun Lu, G. Martinengo, L. Mas, M. Matrosova, Rumyana Micheva, Z. Milanova, L. Miron, Tony Mok, M. Molina, S. Murakami, Y. Nakahara, Tien Nguyen, T. Nishimura, A. Ochsenbein, T. Ohira, Ronny Ohman, C. Ong, G. Ostoros, X. Ouyang, E. Ovchinnikova, O. Ozyılkan, L. Petruželka, Xuan Pham, P. Picon, B. Pikó, A. Poltoratsky, Olga Ponomarova, Patrice Popelkova, G. Purkalne, S. Qin, R. Ramlau, Bernardo Rappaport, Felipe Rey, E. Richardet, J. Roubec, P. Ruff, A. Rusyn, H. Saka, J. Salas, Mario Sandoval, L. Santos, T. Sawa, K. Seetalarom, M. Seker, N. Seki, Freddy Seolwane, L. Shepherd, Sergii Shevnya, A. Shimada, Y. Shparyk, I. Sinielnikov, D. Sirbu, O. Smaletz, João Soares, A. Sookprasert, G. Speranza, V. Sriuranpong, Zinaida Stara, W. Su, S. Sugawara, W. Szpak, Kazuhisa Takahashi, N. Takigawa, Hiroshi Tanaka, Jerry Bing, Q. Tang, P. Taranov, H. Tejada, L. Tho, Yoshitaro Torii, Dmytro Trukhyn, M. Turdean, H. Turna, G. Ursol, J. Vaňásek, M. Varela, M. Vallejo, Luis Vera, A. Victorino, T. Vlásek, I. Vynnychenko, Buhai Wang, Jie Wang, Kai Wang, Yilong Wu, Kazuhiko Yamada, Chih‐Hsin Yang, T. Yokoyama, T. Yokoyama, H. Yoshioka, F. Yumuk, A. Zambrano, J. Zarbá, O. Zarubenkov, Marius Žemaitis, Li Zhang, Xin Zhang, Jun Zhao, Caicun Zhou, Jianying Zhou, Qing Zhou, A. Zippelius (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialThe Lancet, 393
(Awad MM, Gadgeel SM, Borghaei H, . Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol. 2021;16(1):162-168. doi:10.1016/j.jtho.2020.09.01533069888)
Awad MM, Gadgeel SM, Borghaei H, . Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol. 2021;16(1):162-168. doi:10.1016/j.jtho.2020.09.01533069888Awad MM, Gadgeel SM, Borghaei H, . Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol. 2021;16(1):162-168. doi:10.1016/j.jtho.2020.09.01533069888, Awad MM, Gadgeel SM, Borghaei H, . Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol. 2021;16(1):162-168. doi:10.1016/j.jtho.2020.09.01533069888
H. Choy, L. Schwartzberg, S. Dakhil, E. Garon, D. Gerber, J. Choksi, R. Govindan, G. Peng, A. Koustenis, J. Treat, C. Obasaju (2013)
Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 8
(Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1-20. doi:10.5306/wjco.v8.i1.128246582)
Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1-20. doi:10.5306/wjco.v8.i1.128246582Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1-20. doi:10.5306/wjco.v8.i1.128246582, Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1-20. doi:10.5306/wjco.v8.i1.128246582
M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman Rao, K. Hotta, K. Vandormael, A. Riccio, Jing Yang, M. Pietanza, J. Brahmer (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 7
Bilal Anouti, S. Althouse, G. Durm, N. Hanna (2019)
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.Clinical lung cancer
S. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Yokoi, A. Chiappori, K. Lee, M. Wit, B. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Young‐Chul Kim, C. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J. Gray, L. Paz-Ares, J. Carpeño, C. Wadsworth, G. Melillo, Haiyi Jiang, Yi-fan Huang, P. Dennis, M. Özgüroğlu (2017)
Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 377
J. Bradley, R. Paulus, R. Komaki, G. Masters, G. Blumenschein, S. Schild, J. Bogart, Chen Hu, K. Forster, A. Magliocco, V. Kavadi, Y. Garces, S. Narayan, P. Iyengar, C. Robinson, R. Wynn, C. Koprowski, J. Meng, J. Beitler, R. Gaur, W. Curran, H. Choy (2015)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.The Lancet. Oncology, 16 2
K. Chansky, F. Detterbeck, Andrew Nicholson, V. Rusch, Eric Vallières, Patti Groome, Catherine Kennedy, M. Krasnik, Michael Peake, L. Shemanski, V. Bolejack, John Crowley, H. Asamura, R. Rami-Porta (2017)
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung CancerJournal of Thoracic Oncology, 12
(Lin SH, Lin Y, Yao L, . Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC. J Thorac Oncol. 2020;15(2):248-257. doi:10.1016/j.jtho.2019.10.02431778797)
Lin SH, Lin Y, Yao L, . Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC. J Thorac Oncol. 2020;15(2):248-257. doi:10.1016/j.jtho.2019.10.02431778797Lin SH, Lin Y, Yao L, . Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC. J Thorac Oncol. 2020;15(2):248-257. doi:10.1016/j.jtho.2019.10.02431778797, Lin SH, Lin Y, Yao L, . Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC. J Thorac Oncol. 2020;15(2):248-257. doi:10.1016/j.jtho.2019.10.02431778797
H. Borghaei, Corey Langer, L. Paz-Ares, D. Rodríguez-Abreu, B. Halmos, M. Garassino, B. Houghton, T. Kurata, Ying Cheng, Jianxin Lin, M. Pietanza, B. Piperdi, S. Gadgeel (2020)
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trialsCancer, 126
S. Jabbour, A. Berman, R. Decker, Yong Lin, S. Feigenberg, S. Gettinger, C. Aggarwal, C. Langer, C. Simone, J. Bradley, J. Aisner, J. Malhotra (2020)
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.JAMA oncology
M. Nishino, A. Giobbie-Hurder, H. Hatabu, N. Ramaiya, F. Hodi (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.JAMA oncology, 2 12
(Gandhi L, Rodríguez-Abreu D, Gadgeel S, ; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. doi:10.1056/NEJMoa180100529658856)
Gandhi L, Rodríguez-Abreu D, Gadgeel S, ; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. doi:10.1056/NEJMoa180100529658856Gandhi L, Rodríguez-Abreu D, Gadgeel S, ; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. doi:10.1056/NEJMoa180100529658856, Gandhi L, Rodríguez-Abreu D, Gadgeel S, ; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. doi:10.1056/NEJMoa180100529658856
(Gadgeel S, Rodríguez-Abreu D, Speranza G, . Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505-1517. doi:10.1200/JCO.19.0313632150489)
Gadgeel S, Rodríguez-Abreu D, Speranza G, . Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505-1517. doi:10.1200/JCO.19.0313632150489Gadgeel S, Rodríguez-Abreu D, Speranza G, . Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505-1517. doi:10.1200/JCO.19.0313632150489, Gadgeel S, Rodríguez-Abreu D, Speranza G, . Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505-1517. doi:10.1200/JCO.19.0313632150489
(Horinouchi H, Atagi S, Oizumi S, . Real-world outcomes of chemoradiotherapy for unresectable stage III non-small cell lung cancer: the SOLUTION study. Cancer Med. 2020;9(18):6597-6608. doi:10.1002/cam4.330632730697)
Horinouchi H, Atagi S, Oizumi S, . Real-world outcomes of chemoradiotherapy for unresectable stage III non-small cell lung cancer: the SOLUTION study. Cancer Med. 2020;9(18):6597-6608. doi:10.1002/cam4.330632730697Horinouchi H, Atagi S, Oizumi S, . Real-world outcomes of chemoradiotherapy for unresectable stage III non-small cell lung cancer: the SOLUTION study. Cancer Med. 2020;9(18):6597-6608. doi:10.1002/cam4.330632730697, Horinouchi H, Atagi S, Oizumi S, . Real-world outcomes of chemoradiotherapy for unresectable stage III non-small cell lung cancer: the SOLUTION study. Cancer Med. 2020;9(18):6597-6608. doi:10.1002/cam4.330632730697
J. Agulnik, G. Kasymjanova, C. Pepe, M. Hurry, R. Walton, L. Sakr, Victor Cohen, M. Lecavalier, D. Small (2020)
Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.Current oncology, 27 5
W. Curran, R. Paulus, C. Langer, R. Komaki, Jin Lee, S. Hauser, B. Movsas, T. Wasserman, S. Rosenthal, E. Gore, M. Machtay, W. Sause, J. Cox (2011)
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.Journal of the National Cancer Institute, 103 19
(Curran WJ Jr, Paulus R, Langer CJ, . Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/jnci/djr32521903745)
Curran WJ Jr, Paulus R, Langer CJ, . Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/jnci/djr32521903745Curran WJ Jr, Paulus R, Langer CJ, . Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/jnci/djr32521903745, Curran WJ Jr, Paulus R, Langer CJ, . Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/jnci/djr32521903745
L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gümüş, J. Mazières, B. Hermes, F. Senler, T. Csőszi, A. Fülöp, J. Rodríguez-Cid, Jonathan Wilson, S. Sugawara, T. Kato, K. Lee, Ying Cheng, S. Novello, B. Halmos, Xiaodong Li, G. Lubiniecki, B. Piperdi, D. Kowalski (2018)
Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 379
P. Postmus, K. Kerr, M. Oudkerk, S. Senan, D. Waller, J. Vansteenkiste, C. Escriu, S. Peters (2017)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 28 Suppl 4
(Romeu JL. Understanding binomial sequential testing. Accessed October 23, 2017. https://web.cortland.edu/matresearch/BinSeqSTART.pdf)
Romeu JL. Understanding binomial sequential testing. Accessed October 23, 2017. https://web.cortland.edu/matresearch/BinSeqSTART.pdfRomeu JL. Understanding binomial sequential testing. Accessed October 23, 2017. https://web.cortland.edu/matresearch/BinSeqSTART.pdf, Romeu JL. Understanding binomial sequential testing. Accessed October 23, 2017. https://web.cortland.edu/matresearch/BinSeqSTART.pdf
(Mok TSK, Wu YL, Kudaba I, ; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-730955977)
Mok TSK, Wu YL, Kudaba I, ; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-730955977Mok TSK, Wu YL, Kudaba I, ; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-730955977, Mok TSK, Wu YL, Kudaba I, ; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-730955977
(Amin MB, Edge S, Greene F, ; eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.)
Amin MB, Edge S, Greene F, ; eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.Amin MB, Edge S, Greene F, ; eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017., Amin MB, Edge S, Greene F, ; eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
J. Cooper (1997)
Ajcc Cancer Staging Manual
G. Durm, S. Jabbour, S. Althouse, Ziyue Liu, A. Sadiq, R. Zon, S. Jalal, G. Kloecker, M. Williamson, K. Reckamp, R. Langdon, E. Kio, R. Gentzler, B. Adesunloye, W. Harb, R. Walling, M. Titzer, N. Hanna (2020)
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179Cancer, 126
(Bradley JD, Paulus R, Komaki R, . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-199. doi:10.1016/S1470-2045(14)71207-025601342)
Bradley JD, Paulus R, Komaki R, . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-199. doi:10.1016/S1470-2045(14)71207-025601342Bradley JD, Paulus R, Komaki R, . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-199. doi:10.1016/S1470-2045(14)71207-025601342, Bradley JD, Paulus R, Komaki R, . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-199. doi:10.1016/S1470-2045(14)71207-025601342
(Peters S, Felip E, Dafni U, . Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European Thoracic Oncology Platform NICOLAS phase II trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol. 2021;16(2):278-288. doi:10.1016/j.jtho.2020.10.12933188912)
Peters S, Felip E, Dafni U, . Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European Thoracic Oncology Platform NICOLAS phase II trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol. 2021;16(2):278-288. doi:10.1016/j.jtho.2020.10.12933188912Peters S, Felip E, Dafni U, . Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European Thoracic Oncology Platform NICOLAS phase II trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol. 2021;16(2):278-288. doi:10.1016/j.jtho.2020.10.12933188912, Peters S, Felip E, Dafni U, . Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European Thoracic Oncology Platform NICOLAS phase II trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol. 2021;16(2):278-288. doi:10.1016/j.jtho.2020.10.12933188912
(Reck M, Rodríguez-Abreu D, Robinson AG, . Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-546. doi:10.1200/JCO.18.0014930620668)
Reck M, Rodríguez-Abreu D, Robinson AG, . Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-546. doi:10.1200/JCO.18.0014930620668Reck M, Rodríguez-Abreu D, Robinson AG, . Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-546. doi:10.1200/JCO.18.0014930620668, Reck M, Rodríguez-Abreu D, Robinson AG, . Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-546. doi:10.1200/JCO.18.0014930620668
L. Paz-Ares, D. Vicente, A. Tafreshi, A. Robinson, H. Parra, J. Mazières, B. Hermes, I. Çiçin, B. Medgyasszay, J. Cid, I. Okamoto, Sungsook Lee, R. Ramlau, V. Vladimirov, Ying Cheng, Xuan Deng, Ying Zhang, T. Bas, B. Piperdi, B. Halmos (2020)
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(Durm GA, Jabbour SK, Althouse SK, . A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020;126(19):4353-4361. doi:10.1002/cncr.3308332697352)
Durm GA, Jabbour SK, Althouse SK, . A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020;126(19):4353-4361. doi:10.1002/cncr.3308332697352Durm GA, Jabbour SK, Althouse SK, . A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020;126(19):4353-4361. doi:10.1002/cncr.3308332697352, Durm GA, Jabbour SK, Althouse SK, . A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020;126(19):4353-4361. doi:10.1002/cncr.3308332697352
(Garon EB, Rizvi NA, Hui R, ; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028. doi:10.1056/NEJMoa150182425891174)
Garon EB, Rizvi NA, Hui R, ; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028. doi:10.1056/NEJMoa150182425891174Garon EB, Rizvi NA, Hui R, ; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028. doi:10.1056/NEJMoa150182425891174, Garon EB, Rizvi NA, Hui R, ; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028. doi:10.1056/NEJMoa150182425891174
(Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607-1616. doi:10.1001/jamaoncol.2016.245327540850)
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607-1616. doi:10.1001/jamaoncol.2016.245327540850Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607-1616. doi:10.1001/jamaoncol.2016.245327540850, Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607-1616. doi:10.1001/jamaoncol.2016.245327540850
(Senan S, Brade A, Wang LH, . PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.882426811519)
Senan S, Brade A, Wang LH, . PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.882426811519Senan S, Brade A, Wang LH, . PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.882426811519, Senan S, Brade A, Wang LH, . PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.882426811519
E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M. Ahn, E. Felip, Jong-Seok Lee, M. Hellmann, O. Hamid, J. Goldman, J. Soria, M. Dolled-Filhart, R. Rutledge, Jin Zhang, J. Lunceford, Reshma Rangwala, G. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi (2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.The New England journal of medicine, 372 21
(Imfinzi (durvalumab). Package insert. AstraZeneca AB; 2018.)
Imfinzi (durvalumab). Package insert. AstraZeneca AB; 2018.Imfinzi (durvalumab). Package insert. AstraZeneca AB; 2018., Imfinzi (durvalumab). Package insert. AstraZeneca AB; 2018.
(Jabbour SK, Berman AT, Decker RH, . Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2020;6(6):848-855. doi:10.1001/jamaoncol.2019.673132077891)
Jabbour SK, Berman AT, Decker RH, . Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2020;6(6):848-855. doi:10.1001/jamaoncol.2019.673132077891Jabbour SK, Berman AT, Decker RH, . Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2020;6(6):848-855. doi:10.1001/jamaoncol.2019.673132077891, Jabbour SK, Berman AT, Decker RH, . Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2020;6(6):848-855. doi:10.1001/jamaoncol.2019.673132077891
Horinouchi (2020)
6597Cancer Med, 9
(2017)
Understanding binomial sequential testing
S. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Kurata, A. Chiappori, K. Lee, M. Wit, B. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Young‐Chul Kim, C. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J. Gray, L. Paz-Ares, J. Carpeño, C. Faivre-Finn, M. Reck, J. Vansteenkiste, D. Spigel, C. Wadsworth, G. Melillo, Maria Taboada, P. Dennis, M. Özgüroğlu (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCThe New England Journal of Medicine, 379
(2018)
Imfinzi (durvalumab). Package insert
(Chansky K, Detterbeck FC, Nicholson AG, . The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109-1121. doi:10.1016/j.jtho.2017.04.01128461257)
Chansky K, Detterbeck FC, Nicholson AG, . The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109-1121. doi:10.1016/j.jtho.2017.04.01128461257Chansky K, Detterbeck FC, Nicholson AG, . The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109-1121. doi:10.1016/j.jtho.2017.04.01128461257, Chansky K, Detterbeck FC, Nicholson AG, . The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109-1121. doi:10.1016/j.jtho.2017.04.01128461257
C. Clopper, E. Pearson (1934)
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 26
S. Gadgeel, D. Rodríguez-Abreu, G. Speranza, E. Esteban, E. Felip, M. Dómine, R. Hui, M. Hochmair, P. Clingan, S. Powell, Susanna Cheng, Helge Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, E. Garon, S. Novello, B. Rubio-Viqueira, M. Boyer, T. Kurata, J. Gray, Jing Yang, T. Bas, M. Pietanza, M. Garassino (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Durm (2020)
4353Cancer, 126
S. Yoon, T. Shaikh, M. Hallman (2017)
Therapeutic management options for stage III non-small cell lung cancerWorld Journal of Clinical Oncology, 8
(Postmus PE, Kerr KM, Oudkerk M, ; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21. doi:10.1093/annonc/mdx22228881918)
Postmus PE, Kerr KM, Oudkerk M, ; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21. doi:10.1093/annonc/mdx22228881918Postmus PE, Kerr KM, Oudkerk M, ; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21. doi:10.1093/annonc/mdx22228881918, Postmus PE, Kerr KM, Oudkerk M, ; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21. doi:10.1093/annonc/mdx22228881918
S. Peters, M. Reck, E. Smit, E. Smit, T. Mok, M. Hellmann (2019)
How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.Annals of oncology : official journal of the European Society for Medical Oncology
(FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. News release. US Food and Drug Administration. February 20, 2018. Accessed May 20, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc)
FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. News release. US Food and Drug Administration. February 20, 2018. Accessed May 20, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclcFDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. News release. US Food and Drug Administration. February 20, 2018. Accessed May 20, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc, FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. News release. US Food and Drug Administration. February 20, 2018. Accessed May 20, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc
H. Horinouchi, S. Atagi, S. Oizumi, K. Ohashi, Tomohiro Kato, T. Kozuki, M. Seike, T. Sone, T. Sobue, T. Tokito, H. Harada, T. Maeda, T. Mio, Ikue Shirosaka, Kana Hattori, E. Shin, H. Murakami (2020)
Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION studyCancer Medicine, 9
(Ahn JS, Ahn YC, Kim JH, . Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-2666. doi:10.1200/JCO.2014.60.013026150444)
Ahn JS, Ahn YC, Kim JH, . Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-2666. doi:10.1200/JCO.2014.60.013026150444Ahn JS, Ahn YC, Kim JH, . Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-2666. doi:10.1200/JCO.2014.60.013026150444, Ahn JS, Ahn YC, Kim JH, . Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-2666. doi:10.1200/JCO.2014.60.013026150444
J. Bradley, Chen Hu, R. Komaki, G. Masters, G. Blumenschein, S. Schild, J. Bogart, K. Forster, A. Magliocco, V. Kavadi, S. Narayan, P. Iyengar, C. Robinson, R. Wynn, C. Koprowski, M. Olson, J. Meng, R. Paulus, W. Curran, H. Choy (2019)
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
J. Ahn, Y. Ahn, Joo‐Hang Kim, C. Lee, E. Cho, K. Lee, Ming Chen, Dong-Wan Kim, Hoon‐Kyo Kim, Y. Min, J. Kang, J. Choi, Sang-We Kim, G. Zhu, Yi‐Long Wu, Sung Kim, K. Lee, H. Song, Yoon-La Choi, Jong-Mu Sun, Sin-Ho Jung, M. Ahn, Keunchil Park (2015)
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 24
S. Peters, E. Felip, U. Dafni, A. Tufman, M. Guckenberger, R. Álvarez, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martínez-Martí, M. Lambrecht, N. Andratschke, Z. Tsourti, A. Piguet, H. Roschitzki-Voser, A. Gasca‐Ruchti, J. Vansteenkiste, R. Stahel, D. Ruysscher (2020)
Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
PE Postmus, KM Kerr, M Oudkerk (2017)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol, 28
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 378
S. Senan, A. Brade, Lu-hua Wang, J. Vansteenkiste, S. Dakhil, B. Biesma, M. Aguillo, J. Aerts, R. Govindan, B. Rubio-Viqueira, C. Lewanski, D. Gandara, H. Choy, T. Mok, A. Hossain, N. Iscoe, J. Treat, A. Koustenis, B. Antonio, N. Chouaki, E. Vokes (2016)
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 9
(Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413. doi:10.1093/biomet/26.4.404)
Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413. doi:10.1093/biomet/26.4.404Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413. doi:10.1093/biomet/26.4.404, Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413. doi:10.1093/biomet/26.4.404
M. Awad, S. Gadgeel, H. Borghaei, A. Patnaik, J. Yang, S. Powell, R. Gentzler, R. Martins, J. Stevenson, M. Altan, S. Jalal, A. Panwalkar, M. Gubens, L. Sequist, S. Saraf, Bin Zhao, B. Piperdi, C. Langer (2020)
Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
This nonrandomized trial evaluates the treatment outcomes and safety of pembrolizumab plus concurrent chemoradiation therapy in stage III non–small cell lung cancer.
JAMA Oncology – American Medical Association
Published: Sep 4, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.